Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Use of Ibalizumab in HIV
NCT01056393Phase 2Completed
- Sponsor
- Kaiser Permanente
- Start
- Nov 2009
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibalizumab in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Kaiser Permanente. Primary endpoints: HIV-1 Viral Load and CD4+ Cell Count. Started Nov 2009; status: completed.
02
Drugs
ibalizumab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01056393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056393.